TNFRSF17 and Miyoshi myopathy: Interestingly, combination therapy with lenalidomide and CAR-T cells is able to achieve favorable outcomes and improve the cytotoxicity of CAR-T cells (74), and a case report showed that anti-BCMA CAR-T cells combined with lenalidomide were also effective in MM patients refractory to prior anti-BCMA CAR-T cell therapy (75).